Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 2
2002 1
2003 1
2004 2
2005 2
2008 1
2009 2
2010 4
2011 2
2012 4
2014 3
2015 2
2016 2
2017 4
2018 1
2019 2
2021 4
2022 6
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE; LUCENT Study Group. D'Haens G, et al. N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940. N Engl J Med. 2023. PMID: 37379135 Clinical Trial.
A fekélyes vastagbélgyulladás gyógyszeres és sebészeti kezelése.
Miheller P, Kristóf T, Bor R, Farkas K, Golovics P, Harsányi L, Müller KE, Milassin Á, Palatka K, Schäfer E, Szamosi T, Sarlós P, Molnár T. Miheller P, et al. Among authors: kristof t. Orv Hetil. 2024 Mar 12;165(Supplement-1):37-64. doi: 10.1556/650.2024.33050. Print 2024 Mar 12. Orv Hetil. 2024. PMID: 38470491 Hungarian. No abstract available.
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
Danese S, Colombel JF, Lukas M, Gisbert JP, D'Haens G, Hayee B, Panaccione R, Kim HS, Reinisch W, Tyrrell H, Oh YS, Tole S, Chai A, Chamberlain-James K, Tang MT, Schreiber S; GARDENIA Study Group. Danese S, et al. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):118-127. doi: 10.1016/S2468-1253(21)00294-6. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798038 Free article. Clinical Trial.
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV Jr, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ; HICKORY Study Group. Peyrin-Biroulet L, et al. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):128-140. doi: 10.1016/S2468-1253(21)00298-3. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798039 Free article. Clinical Trial.
[Infection risk related to gastrointestinal endoscopic procedures during the SARS-CoV-2 pandemic].
Fábián A, Bor R, Tóth T, Bacsur P, Bálint A, Farkas K, Milassin Á, Molnár T, Resál T, Rutka M, Gelley A, Gyökeres T, Hagymási K, Kovalcsik Z, Kristóf T, Lombay B, Lovik K, Miheller P, Rácz I, Salló Z, Tomcsik Z, Varga M, Vincze Á, Szepes Z. Fábián A, et al. Among authors: kristof t. Orv Hetil. 2022 Nov 13;163(46):1814-1822. doi: 10.1556/650.2022.32633. Print 2022 Nov 13. Orv Hetil. 2022. PMID: 36373579 Hungarian.
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.
Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE; MARINER Investigators. Spyropoulos AC, et al. N Engl J Med. 2018 Sep 20;379(12):1118-1127. doi: 10.1056/NEJMoa1805090. Epub 2018 Aug 26. N Engl J Med. 2018. PMID: 30145946 Free article. Clinical Trial.
[Thromboembolism--risk, prevention and therapy. Practice Guideline].
Magyar Thrombosis és Haemostasis Társaság; Transzfuziológiai és Haematológiai Szakmai Kollégium. Magyar Thrombosis és Haemostasis Társaság, et al. Orv Hetil. 2009 Dec 27;150(52):2335-404. doi: 10.1556/OH.2009.28789. Orv Hetil. 2009. PMID: 20031519 Hungarian. No abstract available.
40 results